SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt’s WCK 5222 gets Accelerated Assessment grant from European Medicines Agency

31 Dec 2025 Evaluate

Wockhardt’s WCK 5222 (combination of Zidebactam 1g + Cefepime 2g) has been granted Accelerated Assessment by The European Medicines Agency (EMA). The Accelerated Assessment designation reflects EMA’s view that WCK 5222 has the potential to address an unmet medical need by providing an effective therapeutic option for the treatment of serious and life-threatening infections, particularly those caused by multi-drug-resistant (MDR) and extremely drug-resistant (XDR) Gram negative pathogens. 

WCK 5222 can be used to address Complicated urinary tract infections (cUTI), including pyelonephritis, Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) and Complicated intra-abdominal infections (cIAI). Further, it can be used for treatment of patients with bacteraemia occurring in association with, or suspected to be associated with, cUTI/acute pyelonephritis, HAP/VAP, or cIAI and treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. 

If approved, the proposed breadth of indications would support the use of WCK 5222 across a wide range of serious infections and contribute to addressing the growing public health challenge of antimicrobial resistance. WCK 5222 represents the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reflecting the advancement of an India-initiated global antimicrobial innovation efforts.

Wockhardt is a research based Global Pharmaceutical and Biotech company.

Wockhardt Share Price

1394.60 1.75 (0.13%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×